SciSparc Ltd
SciSparc Ltd is a biopharmaceutical company focused on developing treatments for serious neurological conditions using innovative drug-based approaches.
Price history of SciSparc Ltd
Price history of SciSparc Ltd
Performance & Momentum
SciSparc-Clearmind File New S. Korea Patent
SciSparc Ltd, a pharmaceutical company focused on treatments for central nervous system disorders, announced the publication of a patent application for a combination treatment for cocaine addiction using psychedelics, in collaboration with Clearmind in South Korea. The news could bolster investor interest in its addiction-treatment pipeline, although the stock fell 10.0% today, likely due to profit-taking or mixed reaction to future regulatory implications.
Strategic Analysis
SciSparc Ltd • 2026
SciSparc Ltd develops innovative treatments targeting serious neurological diseases through biopharmaceutical solutions. Its specialized positioning in neurology places it in a demanding niche, with a research and development-driven model aimed at addressing unmet medical needs.
- Strong specialization in neurology, a field with high technological barriers.
- A model focused on drug innovation, creating potential upside linked to clinical progress.
- Very poor stock performance over several years, reflecting operational or commercial difficulties.
- No recent positive catalyst, as shown by neutral momentum and an intensely competitive environment.
The stock shows particularly weak momentum, with no tangible signs of a near-term turnaround. The lack of favorable news flow and the prolonged deterioration suggest increased caution, negatively affecting its appeal to investors.
Similar stocks to SciSparc Ltd
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
